Literature DB >> 27123140

Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity.

Ya-DI Wang1, Su-Xian Chen2, Li-Qun Ren3.   

Abstract

Observational and experimental studies have produced inconsistent evidence about the association of serum levels of B-type natriuretic peptide (BNP) with anthracycline-induced cardiotoxicity (AIC). Therefore, the current meta-analysis examined the association between serum BNP levels and AIC by using data from high quality studies published in peer-reviewed journals. Relevant studies were identified through literature searches of China National Knowledge Infrastructure (CNKI), Web of Science, PubMed, Google Scolar and China BioMedicine (CBM). STATA software was used in this meta-analysis for statistical analysis. In addition, the crude standardized mean difference (SMD) with 95% confidence interval (CI) for the highest vs. the lowest category of serum BNP levels was calculated. A total of 8 independent case-control studies, containing 126 AIC patients and 569 healthy controls, were included for the current meta-analysis. The results indicated a significant difference in serum BNP levels between the cardiotoxic group and normal group, with respect to post-treatment and pretreatment with anthracyclines. Specifically, the serum levels of BNP increased remarkably after treatment with anthracyclines in the cardiotoxic group, compared with the normal group. No publication bias was detected in this meta-analysis. The findings of the present study provide strong evidence that serum BNP levels may be associated with AIC.

Entities:  

Keywords:  anthracycline-induced cardiotoxicity; case and control study; confidence interval; meta-analysis; post-treatment; pretreatment; serum B-type natriuretic peptide levels; standardized mean difference

Year:  2016        PMID: 27123140      PMCID: PMC4840927          DOI: 10.3892/ol.2016.4424

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Heterogeneity testing in meta-analysis of genome searches.

Authors:  Elias Zintzaras; John P A Ioannidis
Journal:  Genet Epidemiol       Date:  2005-02       Impact factor: 2.135

Review 3.  Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones.

Authors:  Aldo Clerico; Alberto Giannoni; Simona Vittorini; Claudio Passino
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-06       Impact factor: 4.733

4.  Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis.

Authors:  F Song; S Gilbody
Journal:  BMJ       Date:  1998-02-07

5.  Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.

Authors:  David A Morrow; James A de Lemos; Marc S Sabatine; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

6.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Authors:  Henk Visscher; Colin J D Ross; S Rod Rassekh; Amina Barhdadi; Marie-Pierre Dubé; Hesham Al-Saloos; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Andrew M K Brown; Paul C Rogers; Michael S Phillips; Michael J Rieder; Bruce C Carleton; Michael R Hayden
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

7.  Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis.

Authors:  Ivor L Gerber; Ralph A H Stewart; Malcolm E Legget; Teena M West; Renelle L French; Timothy M Sutton; Timothy G Yandle; John K French; A Mark Richards; Harvey D White
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

Review 8.  Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

Authors:  M Aapro; C Bernard-Marty; E G C Brain; G Batist; F Erdkamp; K Krzemieniecki; R Leonard; A Lluch; S Monfardini; M Ryberg; P Soubeyran; U Wedding
Journal:  Ann Oncol       Date:  2010-10-18       Impact factor: 32.976

Review 9.  Natriuretic peptides.

Authors:  Lori B Daniels; Alan S Maisel
Journal:  J Am Coll Cardiol       Date:  2007-12-18       Impact factor: 24.094

10.  Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.

Authors:  Mauro Feola; Ornella Garrone; Marcella Occelli; Antonella Francini; Alberto Biggi; Gianluca Visconti; Fabrizia Albrile; Marco Bobbio; Marco Merlano
Journal:  Int J Cardiol       Date:  2009-11-27       Impact factor: 4.164

View more
  9 in total

Review 1.  Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.

Authors:  Dongqing Chen; Conagh Kelly; Tatt Jhong Haw; Janine M Lombard; Ina I C Nordman; Amanda J Croft; Doan T M Ngo; Aaron L Sverdlov
Journal:  Curr Heart Fail Rep       Date:  2021-11-03

2.  Considerations of biomarker application for cancer continuum in the era of precision medicine.

Authors:  Rayjean J Hung; Elham Khodayari Moez; Shana J Kim; Sanjeev Budhathoki; Jennifer D Brooks
Journal:  Curr Epidemiol Rep       Date:  2022-07-09

Review 3.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 4.  Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

Authors:  Hyungseop Kim; Woo-Baek Chung; Kyoung Im Cho; Bong-Joon Kim; Jeong-Sook Seo; Seong-Mi Park; Hak Jin Kim; Ju-Hee Lee; Eun Kyoung Kim; Ho-Joong Youn
Journal:  J Cardiovasc Ultrasound       Date:  2018-03-28

5.  Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry.

Authors:  Lena Hinrichs; Simone Maria Mrotzek; Raluca-Ileana Mincu; Julia Pohl; Alina Röll; Lars Michel; Amir Abbas Mahabadi; Fadi Al-Rashid; Matthias Totzeck; Tienush Rassaf
Journal:  Front Pharmacol       Date:  2020-05-19       Impact factor: 5.810

6.  Glycogen Phosphorylase Isoenzyme Bb, Myoglobin and BNP in ANT-Induced Cardiotoxicity.

Authors:  Jia-Yin Di; Zong-Xin Zhang; Shao-Jun Xin
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

7.  The Value of Left Atrial Volume Changes in Predicting Cardiotoxicity in Patients Undergoing Anthracycline Chemotherapy.

Authors:  Dongliang Chen; Li Fan; Yifei Rui; Zining Yan
Journal:  J Healthc Eng       Date:  2022-03-24       Impact factor: 2.682

Review 8.  Cardiac imaging in cardiotoxicity: a focus on clinical practice.

Authors:  George Makavos; Ignatios Ikonomidis; Ioannis Paraskevaidis; Michel Noutsias; John Palios; Angelos Rigopoulos; Konstantinos Katogiannis; John Parissis
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

Review 9.  Updates in Anthracycline-Mediated Cardiotoxicity.

Authors:  Canan G Nebigil; Laurent Désaubry
Journal:  Front Pharmacol       Date:  2018-11-12       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.